The first cancer cell therapies were personalized treatments made by isolating and engineering a patient’s own T cells in the lab—a complex, cumbersome, and expensive process. A slew of companies are ...
Bristol Myers Squibb (BMS) drug Abecma was the first FDA-approved CAR T-cell therapy for multiple myeloma, but like other drugs in its class, the treatment’s serious side effect risks limit its use to ...
Bristol Myers Squibb (BMS) and Immatics will develop up to seven cancer cell therapies by launching a new partnership and expanding a three-year-old collaboration inked by BMS predecessor Celgene, the ...
Six weeks after cell and gene therapy manufacturer Cellares revealed that Bristol Myers Squibb would use its innovative robotic production program, the companies have expanded their association. BMS ...
Pharmaceutical giant Bristol Myers Squibb has been quietly growing in the Seattle area. Since acquiring Celgene and its Seattle operations two years ago, BMS now has more than 1,240 employees in the ...
Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers Squibb (BMY) has launched a ...
New approach to adjuvant therapy in high-risk melanoma patients. Background: With the enhanced understanding of the immune response to a tumor, new immunotherapeutic agents may expand treatment ...
Takeda is investing more in cell and gene therapy through new deals with Poseida Therapeutics and Immusoft targeting liver and neurometabolic disorders, respectively. BeiGene's Abraxane China ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback